Background & Rationale for Shorter TPT
- Tuberculosis Preventive Treatment (TPT) halts progression from latent TB infection to active disease, reducing active TB risk by up to $60–90\%$.
- Historical Standard (6H): Daily Isoniazid monotherapy for 6 months suffered from poor adherence ($<40–50\%$ completion rates), prolonged treatment fatigue, and hepatotoxicity risk.
- Current Practice: Short-course rifamycin regimens—specifically 3HP (once-weekly Rifapentine + Isoniazid for 12 weeks) and 3HR (daily Rifampicin + Isoniazid for 3 months)—have superseded 6H globally and in India's National Tuberculosis Elimination Program (NTEP).
High-Yield Comparison Of Modern TPT Regimens
| Parameter | 3HP (Rifapentine + INH) | 3HR (Rifampicin + INH) | 6H (Legacy Isoniazid) |
|---|---|---|---|
| Duration & Frequency | 12 doses: Once weekly for 12 weeks (3 months) | 84–90 doses: Daily for 3 months | 180 doses: Daily for 6 months |
| Age Eligibility | Approved for children $\ge 2\text{ years}$ | Approved for all ages (including infants $<2$ years) | All ages |
| Pill Count | Only 12 doses total; administered directly observed (DOT) or family-supported | Daily administration | Daily administration |
| Completion Rate | $> 85–90\%$ in clinical trials and field cohorts | $> 80–85\%$ | Low ($35–50\%$) |
| Hepatotoxicity Risk | Significantly lower ($<0.5\%$) | Lower than 6H ($<1\%$) | Highest ($1.5–3\%$) |
| Formulation | Dual FDC scored water-soluble tablets available (e.g., HP 150/150 mg or 300/300 mg) | Dispersible dual FDC (HR 50/75 mg) | Plain INH tablets |
Landmark Evidence Base
1. The PREVENT TB Trial (NEJM 2011) & Pediatric Cohort (Lancet ID 2014)
- Assessed 3HP vs 9H in $>8,000$ individuals, including 1,058 children aged 2 to 17 years.
- Pediatric Findings: 3HP was non-inferior to 9H in preventing TB disease ($0.1\%$ vs $0.2\%$, $p<0.001$).
- Treatment completion was markedly superior in the 3HP arm ($88.1\%$ vs $57.4\%$).
- Zero cases of severe hepatotoxicity were recorded in the pediatric 3HP arm.
2. 3HR Trials & Meta-Analyses (Spyridis et al., Diallo et al.)
- Showed equal protective efficacy of 3 months daily HR compared to 6 or 9 months of INH monotherapy.
- Dramatically higher adherence, lower drug-induced liver injury (DILI), and substantially lower healthcare costs.
NTEP 2024 Pediatric TPT Algorithm
flowchart TD
A["Child Contact of Microbiologically Confirmed Pulmonary TB Case"] --> B["<b>Step 1: Clinical Evaluation & Chest X-Ray</b><br>Rule out Active TB Disease<br>(Cough, fever, night sweats, poor weight gain, abnormal CXR)"]
B --> C{"Active TB Excluded?"}
C -->|"No (Signs/Symptoms Present)"| D["Perform Truenat / CBNAAT + Full TB Workup<br>Initiate Multi-Drug Anti-TB Therapy (ATT)"]
C -->|"Yes (Asymptomatic + Clear CXR)"| E{"Age & Weight Category"}
E -->|"Age < 2 Years"| F["<b>Regimen: 3HR</b><br>Daily Rifampicin + Isoniazid for 3 months<br>(Dispersible FDC tablets)"]
E -->|"Age ≥ 2 Years"| G["<b>Regimen: 3HP Preferred</b> (or 3HR)<br>Once-weekly Rifapentine + Isoniazid for 12 weeks<br><i>(12 total doses)</i>"]
F --> H["Monthly clinical follow-up + Adherence check"]
G --> H
NTEP Guidelines for Contact Management
- Under 5 Years: All household contacts of pulmonary TB are eligible for TPT regardless of Tuberculin Skin Test (TST) / IGRA status, after ruling out active TB.
- Aged $\ge 5$ Years: TPT offered to household contacts following active TB screening. Testing for latent infection (TST or IGRA) is encouraged where accessible, but if testing is unavailable, lack of testing must not delay TPT initiation in close contacts.
- Children Living with HIV (CLHIV): TPT is recommended for all CLHIV $\ge 12\text{ months}$ who do not have active TB, regardless of contact history, and infants $<12\text{ months}$ if they have a history of contact.
Drug Dosages And Formulations
1. 3HP Weight-Band Dosing (Once Weekly $\times$ 12 Weeks)
Administered with food. Dual fixed-dose combination or co-blistered tablets.
| Weight Band | Rifapentine (Weekly) | Isoniazid (Weekly) |
|---|---|---|
| $10\text{ to }15\text{ kg}$ | $300\text{ mg}$ | $300\text{ mg}$ |
| $16\text{ to }23\text{ kg}$ | $450\text{ mg}$ | $500\text{ mg}$ |
| $24\text{ to }30\text{ kg}$ | $600\text{ mg}$ | $600\text{ mg}$ |
| $> 30\text{ kg}$ | $750–900\text{ mg}$ | $900\text{ mg}$ |
- Co-prescribe Pyridoxine (Vitamin B6) ($10–25\text{ mg/day}$) in malnourished children and breastfed infants to prevent peripheral neuropathy.
2. 3HR Daily Dosing (Daily $\times$ 3 Months)
- Rifampicin: $15\text{ mg/kg/day}$ (range $10–20\text{ mg/kg}$).
- Isoniazid: $10\text{ mg/kg/day}$ (range $7–15\text{ mg/kg}$).
- Utilizes child-friendly dispersible dual FDC (HR $50/75\text{ mg}$).
Safety, Monitoring, And Drug Interactions
- Urine Discoloration Counseling: Counsel parents that rifamycins turn tears, saliva, and urine orange-red; this is harmless and acts as a marker of compliance.
- Systemic Flu-Like Reactions: Rare with 3HP ($<1\%$ in children); presents as fever, chills, syncope, and dizziness, resolving within 24 hours.
- Drug-Induced Liver Injury (DILI): Much less frequent than with 6H. Baseline liver enzymes are not required unless the child has pre-existing liver disease or concurrent viral hepatitis.
- Drug Interactions: Rifapentine and Rifampicin are potent CYP3A inducers. In HIV-co-infected children on DTG, 3HP is not yet routinely co-prescribed with DTG in $<12$ years; in such cases, 3HR or 6H with adjusted DTG dosing is preferred.